N-terminal acetylation is a specific protein modification that occurs only at the N-terminus but plays a significant role in protein stability, folding, subcellular localization and protein-protein interactions. Computational methods enable finding N-terminal acetylated sites from large-scale proteins efficiently. However, limited by the number of the labeled proteins, existing tools only focus on certain subtypes of N-terminal acetylated sites on frequently detected amino acids. For example, NetAcet focuses on alanine, glycine, serine and threonine only, and N-Ace predicts on alanine, glycine, methionine, serine and threonine. With the growth of experimental N-terminal acetylated site data, it is observed that N-terminal protein acetylation occurs on nearly ten types of amino acids. To facilitate comprehensive analysis, we have developed MTNA (Multiple Types of N-terminal Acetylation), a deep learning network capable of accurately predicting N-terminal protein acetylation sites for various amino acids at the N-terminus. MTNA not only outperforms existing tools but also has the capability to identify rare types of N-terminal protein acetylated sites occurring on less studied amino acids.

The goal of precision oncology is to select more effective treatments or beneficial drugs for patients. The transcription of ‘‘hidden responders’’ which precision oncology often fails to identify for patients is important for revealing responsive molecular states. Recently, a RAS pathway activation detection method based on machine learning and a nature-inspired deep RAS activation pan-cancer has been proposed. However, we note that the activating gene variations found in KRAS, HRAS and NRAS vary substantially across cancers. Besides, the ability of a machine learning classifier to detect which KRAS, HRAS and NRAS gain of function mutations or copy number alterations causes the RAS pathway activation is not clear. Here, we proposed a deep neural network framework for deciphering and identifying pan-cancer RAS pathway activation (DIPRAS). DIPRAS brings a new insight into deciphering and identifying the pan-cancer RAS pathway activation from a deeper perspective. In addition, we further revealed the identification and characterization of RAS aberrant pathway activity through gene ontological enrichment and pathological analysis. The source code is available by the URL https://github.com/zhaoyw456/DIPRAS.